Product
TAcs
Aliases
Kenalog®-40 Injection, TAcs 40 mg, TCA-IR 40, Triamcinolone Acetonide Crystalline Suspension (TAcs)
2 clinical trials
3 indications
Indication
Knee OsteoarthritisIndication
Osteoarthritis of the ShoulderIndication
Osteoarthritis of the HipClinical trial
A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)Status: Completed, Estimated PCD: 2018-03-14
Clinical trial
A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or HipStatus: Completed, Estimated PCD: 2018-10-09